-
-
-
"Mission Accomplished! The Visionary 'Charity Ambassador's' U.S. Trip"
2024-05-09
Visiting international organizations, experiencing a variety of exciting workshops, touring museums and art galleries, city walks through the streets of New York, and interesting soul collisions...The 2024 Emerging Visionaries Awards “Charity Ambassadors” Zheyi Yeand Ko Cheng-ruei, have successfully completed their trip to the USA. What do they have to s
-
-
-
-
Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA
2024-05-06
Shanghai, China, May 6, 2024-Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug application (IND) for phase 3 international multicenter clinical study of Henlius’ novel anti-HER2 mAb, HLX22, in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive advanced gastric cancer has been approve
-
-
-
-
Henlius Trastuzumab Receives FDA Approval in the United States
2024-04-26
·HLX02 (trastuzumab-strf, trade name: HANQUYOU in China, HERCESSI™ in the U.S. and Zercepac®in Europe) is a China-developed mAb biosimilar approved in China, Europe, and U.S.·HLX02 was approved in more than 40 countries and regions around the world, benefiting more than 180,000 patients·Henlius accelerates global expansion, delivering
-
-
-
-
Fosun for Good, Creating IMPACT: Fosun International Issued its 2023 ESG Report and the Second Climate Information Disclosures Report
2024-04-26
(Hong Kong, 26 April 2024) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today issued the Environmental, Social and Governance (ESG) Report 2023 (the “ESG Report”).Facing the increasingly severe challenges of global climate change, Fosun released its second
-
-
-
-
Fosun Pharma’s Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa
2024-04-25
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world.WHO stated that malaria not only continues to directly endanger health and cost lives, but it also perpetuates a vicious cycle of inequity. People living in the most vulnerable situations inclu
-
-
-
-
Wang Qunbin: Fosun Adheres to Globalization Strategy and Continuous Innovation to Create New Momentum
2024-04-22
The Standard Chartered China Summit 2024, hosted by Standard Chartered, was held on 10 April at the Peninsula Shanghai. Wang Qunbin, Co-Chairman of Fosun International, attended the summit and participated in the Fireside Chat Session, where he shared insights on innovation and disruption in a new pattern of global economic development, drawin
-
-
-
-
The Earth Day:Fosun Actively Promotes “Dual Carbon Goals”
2024-04-22
Joining forces to fight the climate crisis has become a global consensus. The 28th UN Climate Change Conference (COP28) resulted in the “UAEConsensus”, which includes a commitment to “transitioning away from allfossil fuels in energy systems, in a just, orderly and equitable manner in thiscritical decade to enable the world to reach net zero emissions by 2050”. Asthe wo
-
-
-
-
The Shenzhen Municipal People's Government and Fosun High Technology Signed Framework Agreement on Strategic Cooperation
2024-04-12
Source: Shenzhen Special Zone DailyDate: 2024.04.12The People's Government of Shenzhen Municipality and Shanghai Fosun High Technology (Group) Co., Ltd. signed a framework agreement on strategic cooperation on 12 April in Shenzhen. Prior to the signing ceremony, Mayor Qin Weizhong met with a delegation led by Guo Guangchang, chairman of Fosun International.QinWeizhong
-
-
-
-
Fosun Enhances Global Operations Through “Deep Mining” to Focus on Core Businesses, Creating Happier Lives for Families Worldwide
2024-04-12
Source: Bloomberg Business Week Online (Chinese Edition)Date: 2024.04.12Xu Xiaoliang, Executive Director and Co-CEO of Fosun InternationalIn 2023, the Group’s core financial indicators performed remarkably, with total revenue reaching RMB198.2 billion in 2023, representing a year-on-year increase of 8.6%. In particular, the total revenue of the four core subsidia
-